(Q35044419)

English

The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Janice P Dutcher

7

object named as

Janice P Dutcher

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Sabina Signoretti

3

object named as

Sabina Signoretti

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

author name string

David F McDermott

1

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Su-Chun Cheng

2

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Kim A Margolin

4

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Joseph I Clark

5

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Jeffrey A Sosman

6

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Theodore F Logan

8

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Brendan D Curti

9

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Marc S Ernstoff

10

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Leonard Appleman

11

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Michael K K Wong

12

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Nikhil I Khushalani

13

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Leslie Oleksowicz

14

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Ulka N Vaishampayan

15

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

James W Mier

16

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

David J Panka

17

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Rupal S Bhatt

18

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Alexandra S Bailey

19

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Bradley C Leibovich

20

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Eugene D Kwon

21

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Fairooz F Kabbinavar

22

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Arie S Belldegrun

23

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Robert A Figlin

24

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Allan J Pantuck

25

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Meredith M Regan

26

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Michael B Atkins

27

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

language of work or name

0 references

publication date

25 November 2014

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Clinical Cancer Research

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

21

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

561-568

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4315731

8 July 2018

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4315731

8 July 2018

Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4315731

8 July 2018

The blockade of immune checkpoints in cancer immunotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4315731

8 July 2018

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4315731

8 July 2018

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4315731

8 July 2018

Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4315731

8 July 2018

Genotypes of NK cell KIR receptors, their ligands, and Fcγ receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4315731

8 July 2018

Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4315731

8 July 2018

Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4315731

8 July 2018

Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4315731

8 July 2018

Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4315731

8 July 2018

Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4315731

8 July 2018

Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4315731

8 July 2018

Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4315731

8 July 2018

Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4315731

8 July 2018

Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4315731

8 July 2018

Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4315731

8 July 2018

Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4315731

8 July 2018

Mature T lymphocyte apoptosis--immune regulation in a dynamic and unpredictable antigenic environment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4315731

8 July 2018

Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4315731

8 July 2018

Correlates of response to IL-2 therapy in patients treated for metastatic renal cancer and melanoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4315731

8 July 2018

Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4315731

8 July 2018

Reporting results of cancer treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4315731

8 July 2018

Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4315731

8 July 2018

Salvage-targeted kidney cancer therapy in patients progressing on high-dose interleukin-2 immunotherapy: the UCLA experience

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4315731

25 October 2018

Carbonic anhydrase IX expression is associated with improved outcome of high-dose interleukin-2 therapy for metastatic renal cell carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4315731

25 October 2018

CA9 gene: single nucleotide polymorphism predicts metastatic renal cell carcinoma prognosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4315731

25 October 2018

Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4315731

25 October 2018

Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4315731

25 October 2018

Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4315731

25 October 2018

Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4315731

25 October 2018

Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4315731

25 October 2018

Renal toxicity of interleukin-2 administration in patients with metastatic renal cell cancer: effect of pre-therapy nephrectomy

1 reference

https://pubmed.ncbi.nlm.nih.gov/25424850

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/25424850

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. Groupe Français d'Immunothérapie, Fédération Nationale des Centres de Lutte Contre le Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/25424850

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-dose interleukin-2 can produce a high rate of response and durable remissions in appropriately selected patients with metastatic renal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/25424850

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1158/1078-0432.CCR-14-1520

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35044419&oldid=2087501441"